HM15136 (efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years with Congenital Hyperinsulinism (CHI)

Hanmi Pharmaceutical

Status and phase

Enrolling

Phase 2

Conditions

Congenital Hyperinsulinism

Treatments

Drug: HM15136

Study type

Interventional

Funder types

Industry

Identifiers

NCT04732416

HM-GCG-201

Details and patient eligibility

About

This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.

Enrollment

16 estimated patients

Sex

All

Ages

2+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female subjects aged ≥2 years with CHI with persistent hypoglycemia despite current SoC treatment according to the investigator's evaluation or documentation
Stable therapy with SoC medications with or without nutritional supplementation
Previously undergone near-total pancreatectomy or being treated with a nonsurgical approach, having been evaluated as not eligible for pancreatic surgery
HbA1c <7%

Exclusion criteria

Subjects with type 1 or type 2 diabetes mellitus
Other reasons for hypoglycemia, including but not limited to drug-induced hyperinsulinemic hypoglycemia, etc
Treatment of CHI with continuous intravenous glucose or glucagon infusion within 3 months prior to screening
Subjects with current use of any drugs that are known to interfere with the study drug, glucose metabolism, or study procedures (eg, use of systemic glucocorticoids [excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled forms] or insulin)
Have conditions that could affect glucose levels such as pheochromocytoma, insulinoma, and glucagonoma